Diagnosis
Primary basis for diagnosis
Imaging evidence
Collateral evidence
Definitive type 1 AIP
Histology
Typical/indeterminate
Histologically confirmed LPSP (level 1 H)
Imaging
Typical
Any non-D level 1/level 2
Indeterminate
Two or more from level 1 (+ level 2 Da)
Response steroid
Indeterminate
Level 1 S/OOI + Rt or level 1 D + level 2 S/OOI/H + Rt
Probable type 1 AIP
Indeterminate
Level 2 S/OOI/H + Rt
Table 53.2
Level 1 and level 2 criteria for type 1 AIP
Criterion | Level 1 | Level 2 |
---|---|---|
P Parenchymal imaging | Typical: Diffuse enlargement with delayed enhancement (sometimes associate with rim-like enhancement) | Indeterminate (including atypicalb) Segmental/focal enlargement with delayed enhancement |
D Ductal imaging (ERP) | Long (>1/3 length of the main pancreatic duct) or multiple strictures without marked upstream dilatation | Segmental/focal narrowing without marked upstream dilatation (duct size, <5 mm) |
S Serology OOI Other organ involvement | IgG4, >2× upper limit of normal value a or b (a). Histology of extrapancreatic organs Any three of the following: (1) Marked lymphoplasmacytic infiltration with fibrosis and without granulocytic infiltration (2) Storiform fibrosis (3) Obliterative phlebitis (4) Abundant (>10 cells/HPF) IgG4-positive cells (b) Typical radiological evidence At least one of the following: (1) Segmental/multiple proximal (hilar/intrahepatic) or proximal and distal bile duct stricture (2) Retroperitoneal fibrosis | IgG4, 1–2× upper limit of normal value a or b (a) Histology of extrapancreatic organs including endoscopic biopsies of bile ductc Both of the following: (1) Marked lymphoplasmacytic infiltration without granulocytic infiltration (2) Abundant (>10 cells/HPF) IgG4-positive cells (b) Physical or radiological evidence At least one of the following: (1) Symmetrically enlarged salivary/lachrymal glands (2) Radiological evidence of renal involvement described in association with AIP |
H Histology of the pancreas | LPSP (core biopsy/resection) At least three of the following: (1) Periductal lymphoplasmacytic infiltrate without granulocytic infiltration (2) Obliterative phlebitis (3) Storiform fibrosis (4) Abundant (>10 cells/HPF) IgG4-positive cells | LPSP (core biopsy) Any two of the following: (1) Periductal lymphoplasmacytic infiltrate without granulocytic infiltration (2) Obliterative phlebitis (3) Storiform fibrosis (4) Abundant (>10 cells/HPF) IgG4-positive cells |
Response to steroid (Rt)a Rapid | Diagnostic steroid trial Rapid (≦2 week) radiologically demonstrable resolution or marked improvement in pancreatic/extrapancreatic manifestations |
Imaging of Pancreatic Parenchyma (on Computed Tomography (CT)/Magnetic Resonance Imaging (MRI))
Typical cases show diffuse enlargement, the so-called “sausage-like appearance” (Fig. 53.1). On dynamic CT and MRI, there is delayed enhancement of the enlarged pancreatic parenchyma. It is sometimes associated with a capsule-like low density rim that surrounds the pancreas on CT, which might be induced by inflammatory and fibrous changes involving the peripancreatic adipose tissue that is rather specific to type 1 AIP [11].
Fig. 53.1
CT imaging of a type 1 AIP case showing diffuse enlargement of pancreatic parenchym a with a capsule-like rim
Imaging of the Pancreatic Duct (Endoscopic Retrograde Cholangiopancreatography (ERCP) or Magnetic Resonance Cholangiopancreatography (MRCP))
Typical cases shows long segmental (>1/3 length) or multiple strictures of the main pancreatic duct. Cases of type 1 AIP with segmental narrowing of the main pancreatic duct are difficult to differentiate from pancreatic cancer. Derivation of branch ducts from the narrowed portion of the main pancreatic duct and skipped narrowed portions of the main pancreatic duct suggest type 1 AIP rather than pancreatic cancer. Upstream dilatation of the distal pancreatic duct is less in cases of type 1 AIP than of pancreatic cancer [11].
Serology (IgG4 Concentration)
Serological criteria consist of elevated serum IgG4 levels . Although the serum IgG4 level is useful for screening, an elevated serum IgG4 level is neither sufficiently sensitive nor specific. About 20 % of patients with type 1 AIP have normal IgG4 levels at presentation [12]. Some studies have shown that 4–10 % of both healthy and disease controls, including patients with pancreatic cancer, have high serum IgG4 concentrations [12–14].
Other Organ Involvement
Sclerosing Cholangitis
Type 1 AIP is commonly accompanied by sclerosing cholangitis [15]. The histology of IgG4-related sclerosing cholangitis (IgG4-SC) shows obliterative phlebitis and transmural fibrosis with dense infiltration of IgG4-positive plasma cells, which lead to stricture of the bile duct.
IgG4-SC must be differentiated from primary sclerosing cholangitis (PSC). Inflammatory bowel disease (IBD) is frequently seen in PSC patients, whereas it is rare in IgG4-SC. Nakazawa et al. reported that the typical findings of IgG4-SC in ERCP are “segmental stricture,” “long stricture with prestenotic dilatation,” and “stricture of the lower bile duct,” while the typical findings of PSC are “band-like stricture,” “beaded appearances,” “pruned-tree appearance,” and “diverticulum-like appearance” [16]. Whether the limited intrapancreatic bile duct stricture associated with AIP should be regarded as a biliary manifestation of IgG4-related disease is controversial, because such stenosis can be induced by compression from the swollen pancreas [17].
IgG4-SC must be also differentiated from cholangiocarcinoma . Neither serum IgG4 concentrations nor cholangiographic findings differentiate these disorders clearly [18]. Endoscopic transpapillary biopsy is generally performed. Although cholangiocarcinoma can be excluded by endoscopic biopsy, the superficial nature of samples obtained by this procedure limits their usefulness for diagnosis of IgG4-SC [19].
Cholecystitis can occur with sclerosing cholangitis. Thickening of the gallbladder wall is detected on imaging, but it is asymptomatic in most cases [20].
Retroperitoneal Fibrosis
Retroperitoneal fibrosis (RF ) is a rare disease characterized by the presence of fibro-inflammatory tissue that develops around the abdominal aorta and iliac arteries. IgG4-related disease is the cause of up to two-thirds of cases of RF [23]. Chiba et al. [24] proposed diagnostic criteria for IgG4-related retroperitoneal fibrosis (IgG4-RF) consisting of three items: typical radiological features, elevation of serum IgG4 levels and the histological finding of an abundant infiltration of IgG4-positive plasma cells at a retroperitoneal mass or extraretroperitoneal sites. In their series of 10 IgG4-RF patients, IgG4-RF showed a predilection for elderly men. Symptoms predominantly related to RF (back pain and edema of the lower extremities) were observed in only two patients, and the remaining patients reported initial symptoms due to associated diseases. Twenty-four other IgG4-related diseases (AIP, sialadenitis, dacryoadenitis, lymphadenopathy, pulmonary pseudotumor, and pituitary pseudotumor) occurred in nine patients. On laboratory examinations, anemia, hypoalbuminemia, increased CRP levels, and antinuclear antigen (ANA) positivity were frequently observed. IgG4-RF responds well to steroids, but malignancies including malignant lymphoma should be ruled out.
Salivary Gland Involvement (Sclerosing Sialadenitis)
Major and minor salivary glands can be affected. This disorder was known for more than a century as Mikulicz’s disease, consisting of dacryoadenitis and enlargement of the parotid and submandibular glands, and it is now recognized as an IgG4-related disease [25]. Isolated enlargement of the submandibular glands is common in IgG4-related disease. In contrast, in Sjogren’s syndrome, parotid enlargement predominates. Xerostomia commonly accompanies IgG4-related disease, but it is generally less severe than in Sjogren’s syndrome, and in contrast to Sjogren’s syndrome, it can improve with immunosuppression.
Orbital Involvement (Dacryoadenitis, Orbital Myositis)
The typical presentation of orbital involvement is swelling within the ocular region or frank proptosis, generally caused by lacrimal-gland enlargement (dacryoadenitis) [26, 27]. Proptosis can also result from orbital pseudotumors that do not affect the lacrimal gland, from involvement of extraocular muscles (orbital myositis), and from combinations of these abnormalities.
Tubulointerstitial Nephritis
The most characteristic form of IgG4-related renal involvement is tubulointerstitial nephritis. The histology of this disease is the same as in other organs: lymphoplasmacytic infiltration with IgG4 predominance among plasma cells; storiform fibrosis; and moderate tissue eosinophilia [28].
Many patients with IgG4-related tubulointerstitial nephritis have substantial enlargements of the kidneys and hypodense lesions evident on CT. The clinical presentation can show advanced renal dysfunction and even end-stage renal dysfunction. Substantial proteinuria can develop, but concentrations are generally subnephrotic.
Histopathology of the Pancreas
The histological profile of the pancreas is LPSP, which shows four characteristic features: (1) periductal lymphoplasmacytic infiltrate without granulocytic infiltration; (2) obliterative phlebitis; (3) storiform fibrosis; and (4) abundant (>10 cells/high power field (HPF)) IgG4-positive cells (Fig. 53.2a–c).
Fig. 53.2
Histopathological findings of the pancreas of a type 1 AIP case. (a) Lymphoplasmacytic sclerosing pancreatitis showing abundant infiltration of plasma cells and lymphocytes and storiform fibrosis (H&E stain). (b) Obliterative phlebitis (EVG stain). (c) Abundant infiltration of IgG4-positive plasma cells (IgG4 immunostaining)
Response to Steroid Therapy
Response to steroid therapy is an additional finding that confirms the diagnosis of AIP. Rapid (within 2 weeks) radiologically demonstrable resolution or marked improvement in pancreatic and extrapancreatic manifestations may support the diagnosis. A diagnostic steroid trial should be conducted carefully only after negative workup for cancer [8].
Treatment and Prognosis
Oral steroid therapy is the standard treatment. Indications for steroid therapy in type 1 AIP patients are symptoms such as jaundice and abdominal pain [29]. Before steroid therapy is started, blood glucose levels and jaundice should be controlled. The most commonly used initial dose of prednisolone is 0.6 mg/kg/day, and it is tapered by 5 mg every 1–2 weeks while monitoring the patient’s symptoms as well as biochemical, serological, and imaging findings. To prevent relapse, maintenance therapy (5 mg/day) is recommended for 6–12 months [29]. Hart et al. [10] reported that of the 978 subjects with type 1 AIP, 302 (31 %) subjects experienced at least one disease relapse. Most relapses of type 1 AIP occurred in the biliary system or pancreas. Subjects with proximal IgG4-SC showed a relatively high relapse rate (56.1 %) compared with subjects without IgG4-SC (25.7 %). At the time of relapse, readministration or increased doses of steroids are usually effective.